Correlation Between Blueprint Medicines and Alnylam Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and Alnylam Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and Alnylam Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Blueprint Medicines Corp and Alnylam Pharmaceuticals, you can compare the effects of market volatilities on Blueprint Medicines and Alnylam Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of Alnylam Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and Alnylam Pharmaceuticals.
Diversification Opportunities for Blueprint Medicines and Alnylam Pharmaceuticals
0.3 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Blueprint and Alnylam is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and Alnylam Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alnylam Pharmaceuticals and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with Alnylam Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alnylam Pharmaceuticals has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and Alnylam Pharmaceuticals go up and down completely randomly.
Pair Corralation between Blueprint Medicines and Alnylam Pharmaceuticals
Given the investment horizon of 90 days Blueprint Medicines is expected to generate 1.14 times less return on investment than Alnylam Pharmaceuticals. But when comparing it to its historical volatility, Blueprint Medicines Corp is 1.1 times less risky than Alnylam Pharmaceuticals. It trades about 0.07 of its potential returns per unit of risk. Alnylam Pharmaceuticals is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest 16,860 in Alnylam Pharmaceuticals on November 3, 2024 and sell it today you would earn a total of 10,271 from holding Alnylam Pharmaceuticals or generate 60.92% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Blueprint Medicines Corp vs. Alnylam Pharmaceuticals
Performance |
| Timeline |
| Blueprint Medicines Corp |
| Alnylam Pharmaceuticals |
Blueprint Medicines and Alnylam Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Blueprint Medicines and Alnylam Pharmaceuticals
The main advantage of trading using opposite Blueprint Medicines and Alnylam Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, Alnylam Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will offset losses from the drop in Alnylam Pharmaceuticals' long position.| Blueprint Medicines vs. Terns Pharmaceuticals | Blueprint Medicines vs. Amylyx Pharmaceuticals | Blueprint Medicines vs. Acumen Pharmaceuticals | Blueprint Medicines vs. Inozyme Pharma |
| Alnylam Pharmaceuticals vs. ProQR Therapeutics BV | Alnylam Pharmaceuticals vs. Wave Life Sciences | Alnylam Pharmaceuticals vs. Blueprint Medicines Corp | Alnylam Pharmaceuticals vs. Apellis Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| CEOs Directory Screen CEOs from public companies around the world |